Not yet independently audited
This page was written from verified sources but has not yet passed the independent citation audit. Treat its claims as provisional.
Last curated: 2026-10-28
Use notes
- DDD-specific population burden is not identifiable from current case definitions; global rows use low-back pain and are labeled accordingly.
- Imaging prevalence is not symptomatic prevalence.
- Treatment rows preserve the study population and comparator; they are not cross-trial rankings.
- Existing figures retain their build/audit provenance. The 2026-09-30 additions were checked against live PubMed EFetch abstracts in this sweep.
2026-10-28 additions
| Figure |
Estimate |
Data/publication year |
Population and method |
Interpretation/source |
| At least mild depressive symptoms, preoperative lumbar DDD |
BDI-II 50/117 (42.7%, 95% CI 34.1–51.8); HADS-D 30/93 (32.3%, 95% CI 23.7–42.2) |
Recruited April 2024–April 2026; publication 2026 |
210 consecutive surgical-selected inpatients, Warsaw; two instrument projects pooled for other analyses, prevalence reported separately |
Not community DDD prevalence; preoperative timing and instrument split are the denominators (Rejner 2026, PMID 42941526; Table 7, PMC13706458). |
| At least mild anxiety symptoms, same cohort |
BAI 86/117 (73.5%, 95% CI 64.7–80.8); HADS-A 50/93 (53.8%, 95% CI 43.7–63.6) |
Same |
Same |
Same limits; BAI/HADS-A cutoffs are not interchangeable (Rejner 2026, PMID 42941526; Table 7). |
| Catastrophizing–affect association after covariate adjustment |
β = 0.639 (depression), β = 0.616 (anxiety); R² 0.488 and 0.489 |
Same |
Multivariable linear regression on z-scored affect, adjusted for age, sex, education, pain duration and intensity |
Cross-sectional, not causal; project membership was not associated with affect (Rejner 2026, PMID 42941526). |
Registry/burden check (2026-10-28): WHO fact sheet and ASR publications page were re-retrieved. ASR still lists a 2026 annual report; tables were not extracted. NICE/VA/DoD/NASS/KCE status is recorded in the guideline registry. A China GBD 2021 reanalysis (Lin 2026, PMID 42747281) was re-screened and not transposed, as on 2026-10-14. SciELO returned HTTP 403; LILACS returned a small JS shell, so regional literature completeness is not asserted.
2026-10-21 burden and registry check
No new numerical estimate was added. The WHO low-back-pain fact sheet and American Spine Registry publications page were retrieved on 2026-10-21. WHO continues to present the existing symptom-based burden estimates. ASR lists its 2026 annual report, but report tables were not extracted in this sweep. Newly retrieved secondary GBD analyses were screened without treating low-back-pain rates or procedure counts as DDD prevalence. Existing statistics retain their earlier source-specific verification dates. SciELO and LILACS could not be searched (HTTP 403 limitation), so this does not establish regional evidence completeness.
2026-10-14 additions
| Figure |
Estimate |
Data/publication year |
Population and method |
Interpretation/source |
| Self-reported back-pain prevalence, global reference curves |
~40% for back pain, the highest of 11 anatomical sites; facial pain ~2% |
Publication 2026 |
6,125,459 participants, 902 population-based sources, 118 countries; harmonised individual-level self-report |
Site-level pain, not DDD or imaging prevalence (Fillingim 2026, PMID 42834228). |
| Late-life back-pain excess, lowest vs highest Human Development Index |
Risk difference 20.2 percentage points (95% CI 19.6–20.9); LBP "approached twice" high-HDI prevalence at the oldest ages |
Publication 2026 |
Same harmonised dataset; HDI-stratified lifespan trajectories |
Read from publisher full text. Contradicts projections of higher burden in high-HDI regions; shown here, not reconciled with GBD (Fillingim 2026, PMID 42834228). |
| Pain burden attributable to smoking, obesity and low income |
18.3% globally; 12.6% sub-Saharan Africa to 27.1% eastern Europe |
Publication 2026 |
Same dataset; all anatomical sites combined |
Combined across sites, not back-specific (Fillingim 2026, PMID 42834228). |
| African LBP prevalence, pooled 2017–2025 studies |
Point 53% (95% CI 40–65; k=8); annual 75% (65–84; k=5); lifetime 65% (54–76; k=13); healthcare workers 80% (79–82; k=6) |
Studies published May 2017–Aug 2025; publication 2026 |
26 studies, 15 countries, 14,339 participants; REML random effects with Hartung-Knapp; GRADE low to moderate |
Heavily occupational and pregnancy-weighted samples, so not a general-population DDD estimate; abstract-level (Nkhata 2026, PMID 42713377). SciELO/LILACS were unreachable (HTTP 403), so regional literature beyond this review was not independently searched. |
| Intradiscal PRP vs control, chronic discogenic LBP |
No significant pain or function difference at any time point; 2 serious adverse events, both after PRP |
RCTs to April 2025; publication 2026 |
Meta-analysis of 11 RCTs, 623 patients; random-effects SMD |
Very low certainty; replicable preparation reported in 1/11 trials. Abstract-level; pooled SMDs not given in the abstract (Madrazo-Ibarra 2026, PMID 42852874). |
Registry/burden check (2026-10-14): no new GBD release specific to low-back pain or the disc was identified in the PubMed window. A GBD-based analysis of LBP in China (PMID 42747281) and one of Ethiopian adults aged ≥55 (PMID 42853621) were screened and not transposed. The ~40% back-pain figure is self-reported site pain and must not be read as a DDD rate.
| Figure |
Estimate |
Data/publication year |
Population and method |
Interpretation/source |
| Smoking-attributable low-back-pain DALYs |
8.67 million; +29.6% since 1990 |
GBD data 1990–2021; publication 2026 |
Secondary GBD 2021 analysis, 204 countries/territories; age-period-cohort and joinpoint models |
Attributable modeled LBP burden, not imaging-defined DDD prevalence or proof of treatment effect; uncertainty interval not supplied in the abstract (Kou 2026, PMID 42688780). |
| BVN-ablation complications |
37/1,145 (3.2%); 25 prolonged radicular-pain events, 24 resolved |
Publication 2026; chart-review dates not supplied in abstract |
Multicenter retrospective treated cohort |
Excluding transient radicular events reduces the reported figure to 13/1,145 (1.1%); retain inclusive rate and ascertainment limitations (Hoelzer 2026, PMID 42765343). |
| Vertebral compression fractures among BVN-device reports |
21/96 reports (21.9%) |
MAUDE through 2025; publication 2026 |
Deduplicated spontaneous/manufacturer device reports |
Report share, not patient incidence; no treated denominator or causal inference (Fischer 2026, PMID 42473615). |
| Pamidronate vs placebo: three-month pain difference |
−6.4 mm (95% CI −22.0 to 9.3); adverse events 54.6% vs 27.3% |
Publication 2026 |
Single-center double-blind RCT, 44 adults with inflammatory-like LBP and Modic type 1; two daily 90-mg IV doses |
Primary pain endpoint did not establish benefit; small sample and imprecision (Soubrier 2026, PMID 42569384). |
Registry/burden check: WHO's live low-back-pain fact sheet still presents the existing global estimates (WHO — “Low back pain”, accessed 2026-09-30). The American Spine Registry publications page lists a 2026 report (accessed 2026-09-30), but this sweep did not establish its release within the requested window or extract a DDD-specific denominator; no headline surgical total was substituted for disease burden. New GBD 2023 Asia-Pacific spinal-pain and broader musculoskeletal analyses were screened but not transposed into DDD estimates.
Global burden of low-back pain
| Figure |
Estimate (95% uncertainty interval) |
Year |
Population |
Method/source |
| Prevalent cases |
619 million (554–694) |
2020 |
204 countries/territories |
GBD Bayesian meta-regression, PMID 37273833 |
| Projected prevalent cases |
843 million (759–933) |
2050 |
Global |
SDI regression × projected population, PMID 37273833 |
| Age-standardized YLD rate |
832/100,000 (578–1,070) |
2020 |
Global |
GBD 2021, PMID 37273833 |
| Age-standardized prevalence-rate change |
−10.4% (−10.9 to −10.0) |
1990–2020 |
Global |
GBD 2021, PMID 37273833 |
| Age-standardized YLD-rate change |
−10.5% (−11.1 to −10.0) |
1990–2020 |
Global |
GBD 2021, PMID 37273833 |
| YLDs attributed to occupational factors, smoking and high BMI |
38.8% (28.7–47.0) |
2020 |
Global low-back-pain YLDs |
Comparative risk assessment, PMID 37273833 |
Asymptomatic imaging prevalence
Source for all rows: systematic review of 33 studies and 3,110 asymptomatic people; generalized linear mixed-effects age model (Brinjikji 2015, PMID 25430861).
| Feature |
Age 20 |
Age 80 |
Population/method |
| Disc degeneration |
37% |
96% |
Asymptomatic CT/MRI cohorts; modeled decade prevalence |
| Disc bulge |
30% |
84% |
Same |
| Disc protrusion |
29% |
43% |
Same |
| Annular fissure |
19% |
29% |
Same |
| Absolute age gradient: degeneration |
— |
+59 percentage points |
Age 80 minus age 20 |
| Absolute age gradient: bulge |
— |
+54 points |
Age 80 minus age 20 |
| Absolute age gradient: protrusion |
— |
+14 points |
Age 80 minus age 20 |
| Absolute age gradient: annular fissure |
— |
+10 points |
Age 80 minus age 20 |
Childhood-to-adult trajectory
| Figure |
Estimate |
Year/age |
Population |
Method/source |
| MRI signal change |
18% |
age 8 |
Healthy schoolchild cohort |
Longitudinal MRI, PMID 36194584 |
| MRI signal change |
10% |
age 11–12 |
Same |
Longitudinal MRI, PMID 36194584 |
| MRI signal change |
38% |
age 18–19 |
Same |
Longitudinal MRI, PMID 36194584 |
| Lifetime low-back pain |
54% |
age 19 |
Same |
Interview; no significant association with signal change, PMID 36194584 |
| ≥1 Pfirrmann grade ≥3 disc |
5% |
age 8 |
40 people with complete four-wave data |
26-year MRI cohort, PMID 41786224 |
| ≥1 Pfirrmann grade ≥3 disc |
12% |
age 11 |
Same |
PMID 41786224 |
| ≥1 Pfirrmann grade ≥3 disc |
48% |
age 19 |
Same |
PMID 41786224 |
| ≥1 Pfirrmann grade ≥3 disc |
72% |
age 34 |
Same |
PMID 41786224 |
| Pfirrmann summary progression |
+0.55/year (0.48–0.63) |
ages 11–19 |
Same |
GEE model, PMID 41786224 |
| Pfirrmann summary progression |
+0.08/year (0.05–0.11) |
ages 19–34 |
Same |
GEE model, PMID 41786224 |
Adult longitudinal MRI
| Figure |
Estimate |
Follow-up |
Population |
Method/source |
| Progression by feature |
7–13% of discs |
5 years |
75 male MZ twin pairs |
Repeated MRI, PMID 16540872 |
| Participants with progression |
7–46% |
5 years |
Same |
Feature dependent, PMID 16540872 |
| New axial annular tears |
1.5% of discs |
5 years |
Same |
MRI, PMID 16540872 |
| Axial tears no longer visible |
2.0% |
5 years |
Same |
MRI, PMID 16540872 |
| New sagittal HIZ |
0.5% |
5 years |
Same |
MRI, PMID 16540872 |
| HIZ no longer visible |
1.6% |
5 years |
Same |
MRI, PMID 16540872 |
| Endplate irregularity increase |
2.1% |
5 years |
Same |
MRI, PMID 16540872 |
| Endplate irregularity decrease |
1.8% |
5 years |
Same |
MRI, PMID 16540872 |
| Familial share of progression variance |
47–66% |
5 years |
Same |
Longitudinal models, PMID 16540872 |
| Loading + resistance-training variance |
2–10% |
5 years |
Same |
Longitudinal models, PMID 16540872 |
| Mean disc-height reduction |
2.2–3.6% |
5 years |
134 male MZ twins |
Quantitative MRI, PMID 18475246 |
| Mean bulge increase L1–L4 |
7–10% |
5 years |
Same |
Quantitative MRI, PMID 18475246 |
| Mean bulge increase L4–S1 |
4% |
5 years |
Same |
Quantitative MRI, PMID 18475246 |
| Occupational lifting variance in height loss |
adjusted R² 4.9% |
5 years |
Same |
Regression, PMID 18475246 |
| Smoking variance in height loss |
adjusted R² 3.5% |
5 years |
Same |
Regression, PMID 18475246 |
| Upper-disc height change |
−8.7% (−1.0 mm) |
15 years |
105 men |
Quantitative MRI, PMID 24262855 |
| Lower-disc height change |
−11.3% (−1.3 mm) |
15 years |
Same |
Quantitative MRI, PMID 24262855 |
| Lumbar L1–S1 shortening |
0.13 mm/year |
15 years |
Same |
Morphometric MRI, PMID 24262855 |
Modic-change natural history
Source: 72 community adults at baseline, 56 at approximately two years (Teichtahl 2017, PMID 27324605).
| Figure |
Estimate |
Population/method |
| Baseline type 1 participants |
3/72 (4.2%) |
Community MRI cohort |
| Baseline type 1 lesions |
6 |
Same |
| Persistent type 1 lesions |
4/6 |
Follow-up MRI |
| Type 1 → type 2 |
2/6 |
Follow-up MRI |
| Baseline type 2 participants |
20/72 (27.8%) |
Community MRI cohort |
| Baseline type 2 lesions |
47 |
Same |
| Incident type 2 lesions |
18 in 7/56 (12.5%) |
Follow-up MRI |
| Type 2 resolution |
1 lesion |
Follow-up MRI |
| Reduced disc height predicting incident type 2 |
OR 1.9 (1.1–3.3) |
Longitudinal association |
| Baseline type 3 participants |
1/72 (1.4%) |
Community MRI cohort |
Risk factors
| Figure |
Estimate |
Population |
Method/source |
| Smoking-associated degeneration |
18% greater mean score |
Identical twins highly discordant for smoking |
Within-pair MRI, PMID 1948392 |
| Heavy vs sedentary work, severe L5–S1 degeneration |
OR 1.86 (1.19–2.92) |
1,022 postmenopausal women |
Adjusted cohort analysis, PMID 35084078 |
| Injury-related height difference |
injured twin +0.3 mm; p=0.302 |
37 injury-discordant MZ pairs |
Within-pair MRI, PMID 20838276 |
| Injury-related maximum-level height difference |
+0.05%; p=0.302 |
Same |
Within-pair MRI, PMID 20838276 |
Pfirrmann measurement reliability
Source: 300 discs in 60 patients, three observers (Pfirrmann 2001, PMID 11568697).
| Figure |
Estimate |
Method |
| Mean patient age |
40 years (range 10–83) |
Reliability sample |
| Grade I discs |
14 |
T2 MRI classification |
| Grade II discs |
82 |
Same |
| Grade III discs |
72 |
Same |
| Grade IV discs |
68 |
Same |
| Grade V discs |
64 |
Same |
| Intraobserver κ |
0.84–0.90 |
Repeated rating |
| Interobserver κ |
0.69–0.81 |
Three readers |
| Exact agreement |
83.8% |
All discs |
| One-grade disagreement |
15.9% |
All discs |
| ≥2-grade disagreement |
1.3% |
All discs |
Exercise and psychological care
| Figure |
Estimate (95% CI) |
Population |
Method/source |
| Exercise trials |
249 |
Chronic nonspecific low-back pain |
Cochrane review, PMID 34580864 |
| Mean age |
43.7 years |
Same |
Review sample |
| Women |
59% average |
Same |
Review sample |
| Pain vs no/usual/placebo |
MD −15.2/100 (−18.3 to −12.2) |
Same |
Moderate certainty, PMID 34580864 |
| Function vs no/usual/placebo |
MD −6.8/100 (−8.3 to −5.3) |
Same |
Below review’s 10-point importance threshold |
| Pain vs other conservative treatment |
MD −9.1/100 (−12.6 to −5.6) |
Same |
Low certainty |
| Function vs other conservative treatment |
MD −4.1/100 (−6.0 to −2.2) |
Same |
Moderate certainty |
| Any adverse effect reported |
33% exercise vs 29% comparison groups |
86 reporting studies |
Mostly minor, PMID 34580864 |
| Psychological-intervention trials |
97 RCTs; 13,136 participants |
Chronic nonspecific low-back pain |
Network meta-analysis, PMID 35354560 |
| CBT + physiotherapy, function post-treatment |
SMD 1.01 (0.58–1.44) |
Same |
Network meta-analysis |
| Pain education + physiotherapy, function post-treatment |
SMD 0.62 (0.08–1.17) |
Same |
Network meta-analysis |
| Behavioral therapy + physiotherapy, pain post-treatment |
SMD 1.08 (0.22–1.94) |
Same |
Network meta-analysis |
Pharmacological evidence
Source: overview of seven Cochrane reviews, 103 studies and 22,238 participants (Cashin 2023, PMID 37014979).
| Figure |
Estimate (95% CI) |
Population/comparator |
| Acute LBP paracetamol pain |
MD +0.49/100 (−1.99 to 2.97) |
Placebo; high certainty |
| Acute LBP paracetamol disability |
MD +0.05/24 (−0.50 to 0.60) |
Placebo |
| Acute LBP NSAID pain |
MD −7.29/100 (−10.98 to −3.61) |
Placebo; moderate certainty |
| Acute LBP NSAID disability |
MD −2.02/24 (−2.89 to −1.15) |
Placebo; high certainty |
| Muscle relaxant adverse events |
RR 1.50 (1.14–1.98) |
Acute LBP; placebo |
| Chronic LBP NSAID pain |
MD −6.97/100 (−10.74 to −3.19) |
Placebo; low certainty |
| Chronic LBP NSAID disability |
MD −0.85/24 (−1.30 to −0.40) |
Placebo |
| Strong-opioid pain |
SMD −0.43 (−0.52 to −0.33) |
Chronic LBP; placebo |
| Strong-opioid disability |
SMD −0.26 (−0.37 to −0.15) |
Chronic LBP; placebo |
| Opioid nausea risk difference |
+0.10 (0.07–0.14) |
Chronic LBP; placebo |
| Opioid constipation risk difference |
+0.07 (0.04–0.11) |
Chronic LBP; placebo |
| Opioid dizziness risk difference |
+0.08 (0.05–0.11) |
Chronic LBP; placebo |
| Antidepressant pain |
SMD −0.04 (−0.25 to 0.17) |
Chronic LBP; placebo |
| Antidepressant disability |
SMD −0.06 (−0.40 to 0.29) |
Chronic LBP; placebo |
STarT Back trial
| Figure |
Estimate (95% CI) |
Population/method |
| Randomized |
851 (568 stratified; 283 control) |
10 English general practices, PMID 21963002 |
| Four-month RMDQ between-group difference |
1.81 (1.06–2.57) |
Intention-to-treat |
| Twelve-month RMDQ difference |
1.06 (0.25–1.86) |
Intention-to-treat |
| Four-month effect size |
0.32 (0.19–0.45) |
Standardized |
| Twelve-month effect size |
0.19 (0.04–0.33) |
Standardized |
| Incremental QALY |
+0.039 |
12 months |
| Mean back-pain healthcare cost |
£240.01 vs £274.40 |
Stratified vs control |
Basivertebral-nerve ablation
| Figure |
Estimate |
Population/method |
| SMART randomized |
225: 147 ablation, 78 sham |
Modic 1/2 chronic axial pain, PMID 29423885 |
| SMART baseline ODI |
42 |
Mean age 47 |
| SMART three-month ODI change |
−20.5 vs −15.2 |
Ablation vs sham; p=0.019 per protocol |
| SMART ≥10 ODI responders |
75.6% vs 55.3% |
Ablation vs sham |
| INTRACEPT randomized |
140 planned; 104 in interim ITT |
Ablation vs standard care, PMID 31229663 |
| INTRACEPT baseline ODI |
46.1 |
Mean age 50 |
| Symptoms ≥5 years |
67.3% |
Interim ITT population |
| Three-month ODI change |
−25.3 vs −4.4 |
Adjusted difference 20.9; p<0.001 |
| Three-month VAS change |
−3.46 vs −1.02 |
Adjusted difference 2.44 cm; p<0.001 |
| ≥10 ODI responders |
74.5% vs 32.7% |
p<0.001 |
Fusion
Source: systematic review of 26 articles and 3,060 fusion participants with ≥12-month validated outcomes (Phillips 2013, PMID 23334400).
| Figure |
Weighted average (SD) |
Method |
| Back-pain VAS improvement |
36.8/100 (14.8) |
Across fusion cohorts |
| ODI improvement |
22.2 (14.1) |
Across fusion cohorts |
| SF-36 physical-component improvement |
12.5 (4.3) |
Across fusion cohorts |
| Satisfaction |
71.1% (5.2%) |
Across studies |
| Radiographic fusion rate |
89.1% (13.5%) |
Across techniques |
| Overall reoperation |
12.5% (12.4%) |
Across studies |
| Index-level reoperation |
9.2% (7.5%) |
Across studies |
Cell and biologic trials: conflicting estimates shown side by side
| Trial/product |
Figure |
Population/method |
Source |
| Disc progenitor, high dose |
VAS −62.8% at 52 weeks |
60-person four-arm randomized phase I/II |
PMID 38925869 |
| Disc progenitor, high dose |
Absolute VAS −42.8 points |
Same |
PMID 38925869 |
| Disc progenitor, high dose |
Disc volume +249.0 mm³ at 52 weeks |
Blinded radiological assessment |
PMID 38925869 |
| Disc progenitor, high dose |
Disc volume +402.1 mm³ at 104 weeks |
Same |
PMID 38925869 |
| Disc progenitor trial |
Severe AEs 18.3%; serious AEs 6.7% |
Serious events all vehicle/placebo, judged unrelated |
PMID 38925869 |
| RESPINE allogeneic BM-MSC |
Primary responders 74% vs 69%; p=0.77 |
114 randomized; MSC vs sham |
PMID 39393844 |
| RESPINE |
No between-group secondary-outcome difference |
12 months |
PMID 39393844 |
| MPC ± HA trial |
404 randomized at 49 sites |
MPC, MPC+HA or saline; 36 months |
PMID 40174800 |
| MPC ± HA trial |
Primary composite not significant |
All randomized participants |
PMID 40174800 |
| MPC+HA subgroup opioid cessation |
27.8% vs 7.8% at 36 months |
Baseline opioid users; duration <68-month subgroup context |
PMID 40174800 |
| Earlier MPC trial |
100 randomized at 13 sites |
6m/18m MPC+HA vs HA/saline |
PMID 33045417 |
Cauda equina and red-flag accuracy
| Figure |
Estimate (95% CI) |
Population/method |
| CES community incidence |
0.3–0.5/100,000/year |
Two community populations, systematic review, PMID 32059184 |
| CES adult community estimate |
0.6/100,000/year |
One population, PMID 32059184 |
| CES working-age estimate |
7/100,000/year |
One population, PMID 32059184 |
| CES among primary-care LBP |
0.08% |
One study, PMID 32059184 |
| CES among secondary-care LBP |
0.27% pooled |
Four studies, PMID 32059184 |
| Confirmed CES among suspected |
19% |
18 studies, mostly UK single-center, PMID 32059184 |
| CES red-flag studies |
7 studies; 569 participants |
MRI reference standard, PMID 31132655 |
| Pooled red-flag sensitivity range |
0.19–0.43 |
Across signs/symptoms, PMID 31132655 |
| Pooled red-flag specificity range |
0.62–0.88 |
Across signs/symptoms, PMID 31132655 |
Deepening sweep: additional discriminating estimates
Population, exposure and measurement
| Figure |
Estimate (95% CI where available) |
Population/method |
Source |
| Composite substantial lumbar degeneration/abnormality |
69.9% |
335 population-based KORA participants; mean age 56.2 years; cross-sectional 3-T MRI |
PMID 36241920 |
| KORA sample composition |
43.3% women; mean BMI 27.7±4.5 kg/m² |
Same |
PMID 36241920 |
| Daytime lumbar-disc height change |
−6.1% (−7.6 to −4.7) to −8.0% (−10.6 to −5.4) |
12 asymptomatic adults aged 18–30; morning-to-evening MRI |
PMID 35072794 |
| Daytime lumbar-disc volume change |
−5.4% (−7.6 to −3.3) to −8.5% (−11.0 to −6.0) |
Same |
PMID 35072794 |
| Maximum posterior L5–S1 deformation |
−13.1% (−16.1 to −10.2) |
Same |
PMID 35072794 |
| Higher occupational loading and imaging degeneration |
OR range 1.6–3.3 |
Four-study meta-analysis; level-specific estimates |
PMID 31656182 |
| Patient-handling health personnel and lumbar disc disease |
OR 2.45 (1.41–4.26) |
Systematic review/meta-analysis; heterogeneous occupational controls |
PMID 32635557 |
| High-intensity zone and abnormal disc morphology |
OR 47.79 (17.07–133.77) |
Meta-analysis against discographic morphology |
PMID 28178999 |
| High-intensity zone and pain reproduction |
OR 8.65 (6.01–15.23) |
Meta-analysis against provocation discography |
PMID 28178999 |
| Radiomics development cohort |
1,397 adults; 737 extracted features |
Northern Finland Birth Cohort; automated segmentation |
PMID 40539398 |
Guideline implementation and treatment interpretation
| Figure |
Estimate (95% CI where available) |
Population/method |
Source |
| Structured exercise: pain |
SMD −0.33 (−0.58 to −0.08) |
Eight RCTs; WHO evidence review; exercise vs no intervention |
PMID 37991647 |
| Structured exercise: functional limitation |
SMD −0.31 (−0.57 to −0.05) |
Eight RCTs; adults and older adults |
PMID 37991647 |
| TENS: immediate pain |
MD −0.90 (−1.54 to −0.26) |
Nine sham-controlled RCTs; approximately 2 weeks |
PMID 37991646 |
| Inappropriate lumbar-imaging referrals, no red flags |
34.8% (27.1–43.3) |
Systematic review/meta-analysis |
PMID 29730460 |
| Fusion-arm repeat surgery at four years |
23% |
Two merged RCTs; 124 total randomized |
PMID 19635718 |
| Rehabilitation-arm crossover to surgery at four years |
24% |
Same |
PMID 19635718 |
| Adjacent-segment radiographic degeneration |
5.9%/year (4.8–7.2) |
31 studies; 4,206 fusion patients |
PMID 26836484 |
| Adjacent-segment clinical disease |
1.8%/year (1.3–2.4) |
Same |
PMID 26836484 |
| Workers’ compensation return to work after fusion |
26–36% |
Published work-related chronic-low-back-pain series summarized in cohort report |
PMID 24231782 |
| Workers’ compensation reoperation after fusion |
22–27% |
Same |
PMID 24231782 |
| RMDQ patients classified improved |
14–51%, depending on method |
447 primary-care consulters; six-month change |
PMID 16360560 |
Red-flag discrimination
| Finding |
Estimate |
Population/method |
Source |
| Major trauma for vertebral fracture |
LR+ 12.8; LR− 0.37 |
Systematic review |
PMID 18177783 |
| Age >50 years for vertebral fracture |
LR+ 2.2; LR− 0.34 |
Same |
PMID 18177783 |
| Bilateral sciatica for MRI-confirmed cauda-equina compression |
sensitivity 32.4%; PPV 17.2%; NPV 88.3% |
260 suspected-CES referrals |
PMID 32475252 |
| Spinal malignancy prevalence among low-back-pain cohorts |
0.1–1.6% |
70-study scoping review |
PMID 41156041 |
These rows are intentionally not merged with earlier estimates. They use different phenotypes, thresholds, settings and comparators.
Known conflicts and caveats
- Low-back-pain burden cannot be assigned to DDD because the GBD case definition is symptom-based.
- Asymptomatic prevalence and symptomatic association are compatible; neither establishes individual causality.
- Cross-sectional age prevalence is not a longitudinal progression rate.
- Twin heritability/familial estimates are population- and phenotype-specific.
- Exercise and psychological estimates come from nonspecific chronic low-back pain, not imaging-defined DDD.
- Pharmacologic trials are generally short relative to chronic exposure and may understate cumulative harms.
- Basivertebral-ablation trials used narrow Modic 1/2 criteria; sponsor involvement and crossover affect interpretation.
- Fusion weighted averages mix techniques, comparators and study designs and should not be treated as randomized causal estimates.
- Cell products are not a class: dose, source, manufacture, carrier and phenotype differ.
- The positive disc-progenitor result and negative RESPINE primary result should not be averaged; they test different products.
- CES estimates vary by denominator and definition; suspected-CES cohorts are heavily UK and single-center.
- MCID thresholds vary with baseline, anchor, intervention and time; threshold crossing is not a universal success definition.
- High-intensity-zone odds ratios use discography-linked reference constructs and are not population diagnostic likelihood ratios.
- Diurnal MRI changes are short-term deformation in young asymptomatic volunteers, not degeneration progression.
- Adjacent-segment radiographic degeneration occurs more often than clinical disease; combining them exaggerates symptomatic burden.